NEW YORK, July  17, 2026  (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share.  The

RPRX

Royalty Pharma declares third quarter 2026 dividend

Royalty Pharma approves Q3 2026 dividend of $0.235 per share

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>NEW YORK, July  17, 2026  (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share.  The</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Royalty Pharma&#039;s board approved a third-quarter 2026 dividend of $0.235 per Class A share, payable Sept 10 to holders of record on Aug 14. The payout reflects ongoing cash flow from its portfolio of royalties across major drugs, including Nurtec ODT and Trikafta. Investors may see a small price adjustment around the Aug 14 ex-dividend date, with continued income potential.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Royalty Pharma approves Q3 2026 dividend of $0.235 per Class A share.</li><li>Dividend payable Sept 10, 2026; record date Aug 14, 2026.</li><li>Portfolio includes 35+ royalties, including Nurtec ODT and Trikafta.</li><li>Ex-dividend date Aug 14, 2026 may trigger modest price move.</li><li>Royalty Pharma is the largest buyer of biopharmaceutical royalties.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Royalty Pharma plc (RPRX)</strong>: Dividend approval signals ongoing cash flow; core business model.</li><li><strong>Vertex Pharmaceuticals (VRTX)</strong>: Royalties on Trikafta and Alyftrek; exposure to Vertex products.</li><li><strong>GlaxoSmithKline (GSK)</strong>: Trelegy royalty exposure; large market.</li><li><strong>Roche Holding (RHHBY)</strong>: Evrysdi royalties; part of portfolio.</li><li><strong>Johnson &amp; Johnson (JNJ)</strong>: Tremfya royalties; diversified product line.</li><li><strong>Pfizer (PFE)</strong>: Nurtec ODT royalties; Xtandi royalties; Pfizer substantial presence.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. Dividend announcements are routine capital-allocation actions that can influence near-term income-focused trading and modest price moves around ex-dividend dates.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Ex-dividend date set for Aug 14, 2026; payout Sept 10, 2026.</li><li>Dividend amount $0.235 per Class A share; predictable quarterly cash flow.</li><li>Portfolio includes royalties on major drugs (Trikafta, Nurtec ODT, Trelegy).</li><li>No portfolio changes announced; upside depends on royalty performance.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Dividend approved July 17, 2026.</li><li>Q3 2026 dividend: $0.235 per Class A share.</li><li>Payment date: September 10, 2026.</li><li>Record date: August 14, 2026.</li><li>Royalty portfolio includes 35+ products.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Neutral stance; income from the dividend supports returns, with limited near-term price catalyst.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>NEW YORK, July  17, 2026  (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/RPRX">RPRX</a>) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share.</p>  <p>The dividend will be paid on September 10, 2026, to shareholders of record at the close of business on August 14, 2026.</p>  <p><strong>About Royalty Pharma plc<br></br></strong>Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson &amp; Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson &amp; Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 19 development-stage product candidates. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=1i35G0O7cazVpoAzUnZ6Q_Sxl06gjhO7C6eFXJqzPSMxrRCGiUYmwZMUvwjqksEm4HDAVrP-5-ZBFtSU_7TSGJReTI4t7Aw1RLTMxNUkmMY=" rel="nofollow" target="_blank">www.royaltypharma.com</a>.</p>  <p><strong>Royalty Pharma Investor Relations and Communications<br></br></strong>+1 (212) 883-6772<br></br><a href="https://www.globenewswire.com/Tracker?data=mBlUsry_PMErHLa_sMfwzBpivoM2I0YBCYWh03DQGtjAFz1hvlqv83KAaS76RdvzivNGIyoZvyYqTCVOuVwrbSxw9s-BoHQ2Axeh1tgt7nE=" rel="nofollow" target="_blank">ir@royaltypharma.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc2NDA4MSM3NzExMjgyIzUwMDEwNTI2NA=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/YzM1MmQ3MTUtOWFiMC00MGE5LTk4NTktYzE4ODkyMjA0NGZkLTUwMDEwNTI2NC0yMDI2LTA3LTE3LWVu/tiny/Royalty-Pharma-plc.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/d605b3b0-7ba0-46e1-a2d4-439ca98694f8"><img src="https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg" border="0" width="150" height="9" alt="Primary Logo"></img></a></p>

Royalty Pharma's board approved a third-quarter 2026 dividend of $0.235 per Class A share, payable Sept 10 to holders of record on Aug 14. The payout reflects ongoing cash flow from its portfolio of royalties across major drugs, including Nurtec ODT and Trikafta. Investors may see a small price adjustment around the Aug 14 ex-dividend date, with continued income potential.

Royalty Pharma declares third quarter 2026 dividend

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News